Skip to main content

Table 3 Time dependent discontinue rate in treatment group compared with placebo

From: Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

 

3 month

6 month

12 month

Placebo

9.28%

16.78%

N/A

Treatment

5.74%

14.24%

22.22%

  1. N/A Not Applicable
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us